Search: onr:"swepub:oai:DiVA.org:liu-188452" >
Effect of N-3 Polyu...
-
Hande, Liv NesseNordland Hosp, Norway; UiT Arctic Univ Norway, Norway
(author)
Effect of N-3 Polyunsaturated Fatty Acids on Lipid Composition in Familial Hypercholesterolemia : A Randomized Crossover Trial
- Article/chapterEnglish2022
Publisher, publication year, extent ...
-
2022-07-27
-
MDPI,2022
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-188452
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-188452URI
-
https://doi.org/10.3390/biomedicines10081809DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding Agencies|Northern Norway Regional Health Authority (Helse Nord RHF) [SFP1311-16]; UiT The Arctic University of Norway
-
Individuals with familial hypercholesterolemia (FH) have an increased risk of cardiovascular disease. Treatment is mainly low-density lipoprotein cholesterol (LDL-C) reduction. How omega-3 polyunsaturated fatty acids (n-3 PUFAs) supplements affect lipoproteins in FH subjects is unknown. We hypothesized that a high-dose n-3 PUFA supplement would reduce atherogenic lipoproteins and influence the high-density lipoprotein cholesterol (HDL-C) function. We performed a randomized, double-blinded crossover study with 34 genetically verified FH individuals (18-75 years, clinically stable, statin treatment > 12 months). Treatment was 4 g n-3 PUFAs (1840 mg eicosapentaenoic acid and 1520 mg docosahexaenoic acid daily) or four capsules of olive oil for three months in a crossover design with a washout period of three months. The defined outcomes were changes in triglycerides, lipoproteins, lipoprotein subfractions, apolipoproteins, and HDL-C function. After treatment with n-3 PUFAs, total cholesterol, LDL-C, and triglycerides were reduced compared to placebo (p <= 0.01 for all). Total HDL-C levels were unchanged, but the subfraction of large HDL-C was higher (p <= 0.0001) after n-3 PUFAs than after placebo, and intermediate HDL-C and small HDL-C were reduced after n-3 PUFAs compared to placebo (p = 0.02 and p <= 0.001, respectively). No changes were found in apolipoproteins and HDL-C function. N-3 PUFAs supplements reduced atherogenic lipoproteins in FH subjects, leaving HDL-C function unaffected.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Kjellmo, ChristianNordland Hosp, Norway; UiT Arctic Univ Norway, Norway
(author)
-
Pettersen, KristinNordland Hosp, Norway
(author)
-
Ljunggren, StefanLinköpings universitet,Avdelningen för prevention, rehabilitering och nära vård,Medicinska fakulteten,Region Östergötland, Arbets- och miljömedicin(Swepub:liu)stelj68
(author)
-
Karlsson, HelenLinköpings universitet,Avdelningen för prevention, rehabilitering och nära vård,Medicinska fakulteten,Region Östergötland, Arbets- och miljömedicin(Swepub:liu)helka90
(author)
-
Cederbrant, KarinLinköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten(Swepub:liu)karce90
(author)
-
Marcusson-Ståhl, MarithaSwedish Toxicol Sci Res Ctr, Sweden
(author)
-
Hovland, AndersNordland Hosp, Norway; UiT Arctic Univ Norway, Norway
(author)
-
Lappegard, Knut ToreNordland Hosp, Norway; UiT Arctic Univ Norway, Norway
(author)
-
Nordland Hosp, Norway; UiT Arctic Univ Norway, NorwayNordland Hosp, Norway
(creator_code:org_t)
Related titles
-
In:Biomedicines: MDPI10:82227-9059
Internet link
Find in a library
To the university's database